Skip to content

ARA-290: Side Effects & Safety

Part of the ARA-290 Complete Guide

Partner

Research Peptides

BioLongevity Labs15% Off
Shop Peptides at BioLongevity Labs

We may earn a commission if you purchase through this link, at no extra cost to you.

Overall Safety Profile

ARA-290 demonstrated a favorable safety profile in Phase 1 and Phase 2 clinical trials, with no serious drug-related adverse events. Crucially, it does not stimulate erythropoiesis — the primary safety concern with EPO-based therapeutics (blood thickening, thrombosis).

Reported Side Effects

  • Injection site reactions: Mild and transient
  • Headache: Occasionally reported
  • No erythropoietic effects: No increase in red blood cells, hematocrit, or thrombosis risk

Important Limitations

Clinical data is limited to Phase 1/2 trials with relatively small patient numbers. Long-term safety beyond 28-day treatment courses has not been characterized. ARA-290 is not yet approved for any indication.

Potential Contraindications

  • Known hypersensitivity to EPO-derived peptides
  • Pregnancy and breastfeeding (no safety data)

Researching peptides? We did the hard part.

Get our free Peptide Starter Kit — the 5 most researched compounds, simplified into one actionable guide.

Related Guides

PI

Peptides Insider Editorial Team

Our content is reviewed for accuracy and grounded in peer-reviewed research where available. We do not provide medical advice. Always consult a qualified healthcare professional.